Amylyx Pharmaceuticals Receives CHMP Negative Opinion On Conditional Marketing Authorization Application For AMX0035 For Treatment Of ALS In The EU, Says Will Seek Re-Examination Of Its Application
Portfolio Pulse from Bill Haddad
Amylyx Pharmaceuticals received a negative opinion from the CHMP on its conditional marketing authorization application for AMX0035, a treatment for ALS in the EU. The company plans to seek re-examination of its application.
June 23, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Amylyx Pharmaceuticals' AMX0035 received a negative opinion from CHMP for its EU marketing application, potentially delaying the treatment's approval. The company plans to seek re-examination.
The negative opinion from CHMP on Amylyx Pharmaceuticals' AMX0035 marketing application in the EU could lead to delays in the treatment's approval, which may negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100